Fact checked by Nick Blackmer The Centers for Disease Control and Prevention (CDC) has expanded the RSV vaccine ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Preliminary findings linking RSV and shingles vaccines to lower dementia risk are intriguing but not conclusive, local ...